Crohn's Disease Treatment Studies

If you are looking for clinical trials for Crohn's disease you have come to the right place! As researchers, our goal is to discover new therapies and information about Inflammatory Bowel Disease (IBD), but most importantly, provide an alternate therapy that helps YOU. We welcome you to the IBD Research Team and encourage you to look at the studies below that you may qualify for. We will update this site periodically, so keep checking this page for new studies. If you have ANY questions or are interested in participating please feel free to call (734) 615-4843 or e-mail higginsSCteam@umich.edu. We hope to hear from you soon!


Carmen – SHP647

A phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled study of SHP647 in subjects with moderate to severe ulcerative colitis

Enrollment status: OPEN

Study Coordinator: Kelli Porzondek

Drug: SHP647; subcutaneous injection (under the skin)

This is a phase 3 study to evaluate the safety and efficacy of SHP647 in patients with moderate to severe Crohn's disease. If eligible, the participant will go through a 12-week induction, 52-week maintenance, and a long-term, open label extension until the drug is approved by the FDA.


M20-259 – risankizumab vs ustekinumab

A phase 3, multicenter, randomized, open label, efficacy assessor-blinded study of risankizumab compared to ustekinumab for the treatment of adult subjects with moderate to severe Crohn's disease who have failed anti-TNF therapy

Enrollment status: TBA

Study Coordinator: Andy Brosius

Drug: IV induction / injection under the skin for maintenance


ABT-494 – upadacitinib

A phase 3 study to evaluate the safety and efficacy of upadacitinib in subjects with moderate to severe Crohn's disease.

Enrollment status: OPEN

Study Coordinator: Jennifer Dixon

Drug: oral tablet

Eligible subjects could be in the study for up to 244 weeks.


GSK – Cosmis

A multicentre, randomised, double-blind, placebo-controlled, repeat dose, dose-ranging phase 2a/2b study to evaluate the safety, tolerability and efficacy of an anti-oncostatin M monoclonal antibody (GSK2330811) in patients with moderate to severe Crohn's disease

Enrollment status: TBA

Study Coordinator: TBA

Drug: injection